Investor Overview

Corporate Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The Company has an innovative and broad pipeline of product candidates that it believes can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug which is currently used off-label for urothelial cancer ...More>>

URGN (Common Stock) $56.850.00 (0.00%)04/20/18 4:00 p.m. ET
Stock chart for: URGN.O.  Currently trading at $56.85 with a 52 week high of $66.38 and a 52 week low of $13.01.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming Events
Urogen Pharma at The 113th American Urological Association’s (AUA) Annual Meeting
Monday, May 21, 2018 10:40 a.m. PT
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Urogen Pharma posts new information to the site. Just enter your e-mail address and click Submit.